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Our understanding of the formation of
tumor vessels by vasculogenesis is in its
infancy compared to our understanding
of vessel formation by angiogenesis.
Angiogenesis involves migration and
proliferation of endothelial cells of exist-
ing vessels. Postnatal vasculogenesis is
thought to involve endothelial progeni-
tors, a subset of bone marrow-derived
cells (BMDCs, Figure 1). Two recent
reports—De Palma et al. (2003) and
Garcia-Barros et al. (2003)—
offer conflicting data on the
incorporation of BMDCs in
tumor vessels using some of
the same tumor models.
These findings are significant
because of their clinical
implications and timely
because of the exciting
developments in the field of
stem cell biology. However,
they raise many important
questions about the biology
of BMDCs.
In 1997, Isner and
coworkers reported the
existence of putative 
endothelial progenitor cells—
angioblasts—in adults, and
proposed the bone marrow
as a source of these cells
(Asahara et al., 1997).
Initially, these ideas stirred
intense controversy and gen-
erated great skepticism. Six
years later, the existence of
endothelial progenitor cells
and their involvement in ves-
sel formation is widely
accepted, but the controver-
sy has shifted to their role in
solid tumors. Emerging
initially as an unexpected
contribution of the bone
marrow to tumor endothelium
(Takahashi et al., 1999), the
focus shifted to the molecular
characterization of BMDCs.
Rafii and coworkers defined
endothelial progenitor cells as VEGFR2-
(vascular endothelial growth factor
receptor 2) positive BMDCs. However,
these authors reported that VEGFR1-
positive BMDCs also home to tumors,
contributing indirectly to neovasculariza-
tion. They provided genetic evidence for
the critical role of bone marrow in tumor
neovascularization by rescuing tumor
growth and angiogenesis in Id mutant
mice—which have defective angiogene-
sis—by transplanting bone marrow from
wild-type/nonmutant mice (Lyden et al.,
2001). Simultaneously, Carmeliet and
coworkers reported rescuing patho-
logical angiogenesis in placental growth
factor (PlGF) null mice by transplanting
bone marrow from nonmutant mice
(Carmeliet et al., 2001).
In the May 16 issue of Science,
Garcia-Barros et al. (2003) offer com-
pelling evidence for the critical role of
BMDCs in solid tumor
growth in nonmutant mice.
Bone marrow cells trans-
planted from Rosa-26
mice—which express β-
galactosidase—formed about
half of the tumor-vascular
endothelium. These authors
propose endothelial apopto-
sis as a key determinant of
the tumor response to
ionizing radiation treatment.
By knocking out the Acid
Sphingomyelinase gene,
responsible for the endothe-
lial apoptosis, the authors
show that a transplant of 
Acid Sphingomyelinase null
BMDCs was sufficient to
reduce significantly the radi-
ation sensitivity of the
tumors.
The findings of De Palma
et al. (2003), published online
on May 12 in Nature Medicine,
also attest to the critical role
played by BMDCs in the neo-
vascularization and growth 
of mouse tumor xenografts.
However, despite using
multiple and efficient vector
constructs for gene transfer of
the green fluorescence protein
(GFP), and constitutive GFP-
bone marrow cells transplants,
these authors report the
absence of GFP-positive cells
in tumor endothelium. This
unexpected result was consis-
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The role of bone marrow-derived cells in tumor neovascularization is currently the subject of intense research and debate.
Two recent studies (De Palma et al., 2003 and Garcia-Barros et al., 2003) offer novel yet somewhat conflicting evidence for
the role of these cells in tumor growth and neovascularization.These results have significant implications for tumor biolo-
gy and treatment. At the same time, they raise many questions, which must be addressed for translating these important
findings into new, improved treatment strategies.
Figure 1. Partiicipation of bone marrow-derived cells in tumor neovas-
cularization
Tumors overexpress angiogenic growth factors such as VEGF, PlGF,
and Ang1. These growth factors augment mobilization of bone mar-
row cells, which in turn facilitate the tumor neovascularization. These
cell populations include VEGFR2+ endothelial progenitor cells (EPCs)
that purportedly form tumor endothelium, and Tie2+ mononuclear
cells (TEMs), which control indirectly the angiogenesis during tumor
growth and liver regeneration. Two recent reports offer novel insights
into the role of BMDCs in tumor angiogenesis. However, the data on
BMDC incorporation in angiogenic vessels are conflicting, even for
the same tumor cell lines. It is also not clear if these TEMs are the
VEGFR1+ hematopoietic precursors previously described by Hattori et
al. (2002) as the stem cells responsible for hematopoietic reconstitu-
tion. Whereas the molecular definition of these cells, the extent and
kinetics of their incorporation into vessel wall, and the mechanisms
involved are largely unknown, these findings have multiple therapeu-
tic implications and warrant urgent and careful mechanistic and
phenotypic characterization. Figure courtesy of Dr. Lance L. Munn.
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tently observed in three different tumor
lines, including B16 melanoma—a line
used by Garcia-Barros et al. in their stud-
ies. The reasons for these diametrically
opposite results are not known. Of inter-
est, De Palma et al. discovered a new
subset of BMDCs that are involved in
postnatal angiogenesis. Expression of
GFP under an endothelial-specific (Tie2)
promoter/enhancer revealed that bone
marrow contribution to the tumor vessels
in their setting relied not on the endothe-
lial progenitor cells, but rather on a
hematopoietic (i.e., CD45- and CD11b-
positive, but CD31-negative) cell popula-
tion—Tie2-expressing mononuclear cells
(TEMs).These TEMs home specifically to
the tumors and contribute indirectly to
neovascularization; hence, they offer an
ideal platform for cell-based gene delivery
to solid tumors.
The new data of De Palma et al.
broaden the view on the involvement of
the bone marrow in tumor angiogenesis
(Figure 1) and highlight the limits of our
current understanding of the relationship
between cell subsets and physiologic
function. For example, Rafii and cowork-
ers proposed the notion that the
VEGFR1-positive stem cells mobilized by
angiogenic factors such as VEGF and
PlGF may actually be responsible for res-
cuing hematopoiesis following chemo- or
radiation-induced injury of the bone mar-
row (Hattori et al., 2002). It is not clear
whether the TEMs share features with
cell types such as VEGFR1-positive
BMDCs. On a related subject, work from
Verfaillie’s laboratory established ex vivo
the existence of multipotent adult progen-
itor/stem cells in the bone marrow (Jiang
et al., 2002). However, there is a strong
debate on the extent of hematopoietic
stem cell multipotency and transdifferen-
tiation capacity (Wagers et al., 2002).
These controversies call for urgent char-
acterization of the molecular definition of
various subsets of BMDCs and mecha-
nisms involved in their function.
Conflicting data notwithstanding,
these findings have important clinical
implications for physiological and patho-
logical angiogenesis. The possibility of
selective gene delivery and/or autolo-
gous cell transplants that would target
pathologic angiogenesis specifically and
efficiently is of great interest to immunol-
ogists and gene therapists alike. Equally
important, understanding the biology of
the tumor-endothelial response to radia-
tion is critical for improving the existing
therapies and designing more efficient
strategies. Lastly, research on BMDCs
has an impact beyond the field of oncolo-
gy. A recent clinical trial showed that infu-
sion of autologous progenitor cells has
great promise in alleviating limb
ischemia (Tateishi-Yuyama et al., 2002).
Tissue engineering and regenerative
medicine await further insight into the
biology of these cells. Generating new
functional vasculature based on
progenitor cells could prove crucial for
these fields.
Despite the consensus on the impor-
tant role of BMDCs, several critical ques-
tions remain unanswered. Why is the
extent of incorporation of endothelial
progenitor cells in these two studies diff-
erent? Is the extent of incorporation
dependent on factors such as tumor
size, tumor type, site, host, or genetic
marker? Is it similar in transplanted ver-
sus spontaneous tumors? Which adhe-
sion molecules are involved in cell
homing? Do the growth factors produced
by tumors mobilize these cells and also
upregulate adhesion molecules on the
angiogenic endothelium (Melder et al.,
1996)? Do these cells adhere to the ves-
sel luminally or reside abluminally, and
thus provide appropriate growth factors?
Or do they incorporate in the vessel
wall? If so, what are the kinetics of cell
incorporation? Do these cells proliferate
after they are incorporated? Do they
extravasate and transdifferentiate into
mural cells after they are incorporated?
How specific is their contribution to tumor
vessels? What is the role of these cells in
response to cancer treatment with
antiangiogenic therapy, chemotherapy,
radiation therapy, or combination ther-
apy? Can progenitor cell kinetics in the
circulation of patients be used as an
independent marker for diagnosis or
prognosis? Intravital microscopy coupled
with the use of transgenic technologies
and mathematical modeling has the
potential to address several of these
questions (Jain et al., 2002; Stoll et al.,
2003). Comprehensive correlative stud-
ies in clinical trials can also provide valu-
able insight into these issues in human
disease. Eventually, these integrated
findings will allow the safe and efficient
translation from bench to the bedside.
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